NASDAQ:LYRA

Lyra Therapeutics (LYRA) Stock Forecast, Price & News

$3.88

-0.03 (-0.77%)

(As of 04:00 PM ET)

Compare

Today's Range: $3.73
▼
$4.03
50-Day Range: $3.09
▼
$4.80
52-Week Range: $1.86
▼
$5.67

Volume: 101,465 shs
Average Volume: 186,915 shs
Market Capitalization: $192.25 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.67

Lyra Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 302.7% Upside
$15.67 Price Target
Short Interest: Healthy
0.85% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.30
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.42) to ($1.27) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.24 out of 5 stars

Medical Sector

376th out of 969 stocks

Surgical & Medical Instruments Industry

48th out of 100 stocks

3.5

Analyst's Opinion

Consensus Rating
Lyra Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $15.67, Lyra Therapeutics has a forecasted upside of 302.7% from its current price of $3.89.
Amount of Analyst Coverage
Lyra Therapeutics has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.85% of the outstanding shares of Lyra Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Lyra Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Lyra Therapeutics has recently increased by 661.48%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Lyra Therapeutics does not currently pay a dividend.
Dividend Growth
Lyra Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LYRA.

2.9

News and Social Media Coverage

News Sentiment
Lyra Therapeutics has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Lyra Therapeutics this week, compared to 1 article on an average week.
Search Interest
5 people have searched for LYRA on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.
MarketBeat Follows
6 people have added Lyra Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Lyra Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
17.42% of the stock of Lyra Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
80.20% of the stock of Lyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Lyra Therapeutics are expected to grow in the coming year, from ($1.42) to ($1.27) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Lyra Therapeutics is -2.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Lyra Therapeutics is -2.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Lyra Therapeutics has a P/B Ratio of 1.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Lyra Therapeutics (NASDAQ:LYRA) Stock

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

LYRA Price History

30 days | 90 days | 365 days | Advanced Chart

LYRA Stock News Headlines

September 13, 2023 | finance.yahoo.com

Lyra (LYRA) Posts Upbeat Data on Rhinosinusitis Study, Stock Up

September 12, 2023 | nasdaq.com

B of A Securities Maintains Lyra Therapeutics (LYRA) Buy Recommendation

October 2, 2023 | Legacy Research (Ad)

Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video)

“Hi, I’m Teeka Tiwari...I’m about to get in this Tesla and drive up to a facility just a few miles from here to show you what could be the secret behind Elon Musk’s new AI project… What happens next will shock you…”

September 12, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Lyra Therapeutics (LYRA)

September 12, 2023 | marketwatch.com

Lyra Therapeutics Phase 2 Chronic Rhinosinusitis Study Hits Main Endpoint >LYRA

September 12, 2023 | marketwatch.com

Lyra Therapeutics Shares Rise Premarket on Phase 2 Study Success

September 12, 2023 | markets.businessinsider.com

Lyra Therapeutics Reports Positive Topline Results From BEACON Phase 2 Study Of LYR-220

September 12, 2023 | finance.yahoo.com

Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery

October 2, 2023 | Legacy Research (Ad)

Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video)

September 6, 2023 | finance.yahoo.com

Lyra Therapeutics to Participate in Upcoming Investor Conferences

August 31, 2023 | finance.yahoo.com

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

August 31, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Evotec AG (EVO), Lyra Therapeutics (LYRA) and Alpine Immune Sciences (ALPN)

August 29, 2023 | finance.yahoo.com

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

August 8, 2023 | finance.yahoo.com

Lyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

July 20, 2023 | msn.com

Lyra Therapeutics: Worthy Of A Small Bet

July 13, 2023 | finance.yahoo.com

Lyra Therapeutics to Present at William Blair Virtual Biotechnology Conference

June 27, 2023 | benzinga.com

Lyra Therapeutics President & CEO Awarded $610K Worth of Stock Options

June 26, 2023 | msn.com

Lyra Therapeutics: Bob Langer-Founded Company Shows Promising Data For Sinus Treatment

June 9, 2023 | morningstar.com

Lyra Therapeutics Inc Ordinary Shares

June 6, 2023 | 247wallst.com

Lyra Therapeutics Extends Gains After Insider Transactions Disclosures

June 3, 2023 | marketwatch.com

Stocks to Watch: Lyra Therapeutics, Natuzzi, Samsara

June 2, 2023 | marketwatch.com

Lyra Therapeutics Shares Rise 11% as Investors Boost Holdings

June 2, 2023 | finance.yahoo.com

Lyra Therapeutics to Present at Jefferies Healthcare Conference

June 1, 2023 | finance.yahoo.com

Lyra Therapeutics Announces Closing of $50.0 Million Private Placement

May 26, 2023 | msn.com

Lyra Therapeutics announces $50M private placement

May 26, 2023 | finance.yahoo.com

Lyra Therapeutics Announces $50.0 Million Private Placement

May 14, 2023 | finance.yahoo.com

Lyra Therapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags

See More Headlines

Receive LYRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LYRA Company Calendar

Last Earnings: 8/08/2023
Today: 10/02/2023
Next Earnings (Estimated): 11/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:LYRA
CUSIP: N/A
CIK: 1327273
Web: www.lyratherapeutics.com
Phone: 617-393-4600
Fax: N/A
Employees: 73
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $15.67
High Stock Price Forecast: $20.00
Low Stock Price Forecast: $12.00
Forecasted Upside/Downside: +300.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.56)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-55,280,000.00
Net Margins: -4,917.12%
Pretax Margin: -4,913.97%
Return on Equity: -70.42%
Return on Assets: -53.11%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.38
Quick Ratio: 8.38

Sales & Book Value

Annual Sales: $1.36 million
Price / Sales: 142.46
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.54 per share
Price / Book: 1.54

Miscellaneous

Outstanding Shares: 49,550,000
Free Float: 40,915,000
Market Cap: $193.74 million
Optionable: Not Optionable
Beta: -0.20

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Dr. Harlan W. Waksal M.D. (Age 70)
Exec. Chairman
Comp: $214.06k

Dr. Maria Palasis Ph.D. (Age 58)
CEO, Pres & Director
Comp: $865.15k

Dr. Richard Nieman M.D. (Age 60)
Chief Medical Officer
Comp: $606.7k

Dr. Carmichael S. Roberts Jr. (Age 55)
Ph.D., Co-Founder

Mr. Jason Cavalier (Age 50)
CFO, Treasurer & Sec.

Mr. Ray Knox
VP of Operations

Dr. John E. Bishop Ph.D. (Age 61)
Chief Technology Officer

Ms. Ellen Cavaleri
Sr. VP of Investor Relations & Communications

Ms. Corinne Noyes (Age 55)
Sr. VP of Commercial Strategy & Market Devel.

Ms. Vineeta Belanger Ph.D.
Sr. VP of Clinical Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

LYRA Stock - Frequently Asked Questions

Should I buy or sell Lyra Therapeutics stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lyra Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LYRA shares.
View LYRA analyst ratings or view top-rated stocks.
What is Lyra Therapeutics' stock price forecast for 2023?: 3 analysts have issued 1 year target prices for Lyra Therapeutics' shares. Their LYRA share price forecasts range from $12.00 to $20.00. On average, they expect the company's stock price to reach $15.67 in the next twelve months. This suggests a possible upside of 300.7% from the stock's current price.
View analysts price targets for LYRA or view top-rated stocks among Wall Street analysts.
How have LYRA shares performed in 2023?: Lyra Therapeutics' stock was trading at $3.14 at the beginning of 2023. Since then, LYRA stock has increased by 24.5% and is now trading at $3.91.
View the best growth stocks for 2023 here.
Are investors shorting Lyra Therapeutics?: Lyra Therapeutics saw a increase in short interest in September. As of September 15th, there was short interest totaling 421,100 shares, an increase of 661.5% from the August 31st total of 55,300 shares. Based on an average daily volume of 348,200 shares, the days-to-cover ratio is currently 1.2 days.
View Lyra Therapeutics' Short Interest.
When is Lyra Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our LYRA earnings forecast.
How were Lyra Therapeutics' earnings last quarter?: Lyra Therapeutics, Inc. (NASDAQ:LYRA) announced its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.11. The company earned $0.46 million during the quarter, compared to the consensus estimate of $0.41 million. Lyra Therapeutics had a negative net margin of 4,917.12% and a negative trailing twelve-month return on equity of 70.42%.

What other stocks do shareholders of Lyra Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Lyra Therapeutics investors own include Pfizer (PFE), DocuSign (DOCU), Intel (INTC), OPKO Health (OPK), Valero Energy (VLO), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Gilead Sciences (GILD), Micron Technology (MU) and ONEOK (OKE).
When did Lyra Therapeutics IPO?: (LYRA) raised $52 million in an initial public offering on Friday, May 1st 2020. The company issued 3,500,000 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and William Blair acted as the underwriters for the IPO and BTIG was co-manager.
What is Lyra Therapeutics' stock symbol?: Lyra Therapeutics trades on the NASDAQ under the ticker symbol "LYRA."
How do I buy shares of Lyra Therapeutics?: Shares of LYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Lyra Therapeutics' stock price today?: One share of LYRA stock can currently be purchased for approximately $3.91.
How much money does Lyra Therapeutics make?: Lyra Therapeutics (NASDAQ:LYRA) has a market capitalization of $193.74 million and generates $1.36 million in revenue each year. The company earns $-55,280,000.00 in net income (profit) each year or ($1.56) on an earnings per share basis.
How can I contact Lyra Therapeutics?: Lyra Therapeutics' mailing address is 480 ARSENAL STREET, WATERTOWN MA, 02472. The official website for the company is www.lyratherapeutics.com. The company can be reached via phone at 617-393-4600 or via email at laurence@gilmartinir.com.

This page (NASDAQ:LYRA) was last updated on 10/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial